Concordance Between Active Partial Thromboplastin Time and Anti-Factor Xa Assays in Neurocritically Ill Patients Receiving Subcutaneous Heparin Prophylaxis

被引:0
|
作者
Shinn, Grace [1 ]
Berger, Karen [2 ]
Roh, David [3 ]
Doyle, Kevin [3 ]
Boehme, Amelia K. [3 ]
Connolly, Edward Sander [4 ]
Park, Soojin [3 ]
Agarwal, Sachin [3 ]
Claassen, Jan [3 ]
Der-Nigoghossian, Caroline [1 ,5 ]
机构
[1] Columbia Univ, NewYork Presbyterian Hosp, Dept Pharm, Irving Med Ctr, New York, NY USA
[2] Weill Cornell Med Ctr, NewYork Presbyterian Hosp, Dept Pharm, New York, NY USA
[3] Columbia Univ, NewYork Presbyterian Hosp, Dept Neurol, Irving Med Ctr, New York, NY USA
[4] Columbia Univ, NewYork Presbyterian Hosp, Dept Neurosurg, Irving Med Ctr, New York, NY USA
[5] Columbia Irving Med Ctr, NewYork Presbyterian Hosp, Dept Pharm, 622 West 168th St, New York, NY 10032 USA
来源
NEUROHOSPITALIST | 2023年 / 13卷 / 03期
关键词
unfractionated heparin; neurocritical care; activated partial thromboplastin time; anti-factor Xa; UNFRACTIONATED HEPARIN; VENOUS THROMBOEMBOLISM; PREVENTION; THROMBOSIS; WEIGHT; VALUES; APTT; CARE;
D O I
10.1177/19418744231159917
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Laboratory monitoring is not recommended when subcutaneous unfractionated heparin (SQ-UFH) is administered at prophylactic doses. However, aPTT prolongation and associated hemorrhage has been reported in the neurocritically ill. At our institution, Neuroscience Intensive Care Unit (Neuro-ICU) patients with prolonged aPTT are further evaluated with a follow up aPTT and anti-factor Xa. Purpose The purpose of this study was to describe concordance between aPTT and anti-factor Xa in neurocritically ill patients receiving prophylactic SQ-UFH with evidence of aPTT prolongation. Methods A retrospective chart review of adult patients admitted to the Neuro-ICU from June 2017 to June 2019 was performed. Patients were included if they received SQ-UFH with aPTT levels and at least one anti-factor Xa level drawn within one hour of each other. Concordance between paired aPTT and anti-factor Xa was evaluated using Cohen's weighted kappa. Results Forty two patients with 56 paired aPTT and anti-factor Xa levels were included. The most prescribed SQ-UFH regimen was 5000 units every 8 hours (60.7%) and anti-factor Xa levels were drawn a median (IQR) of 5.7 (3.1-10.7) hours after the SQ-UFH dose. Only 16 (28.6%) pairs were in concordance. The analysis showed a weighted kappa of .09; 95% CI [-.05 to .22] indicating poor agreement. Conclusions In neurocritically ill patients receiving prophylactic SQ-UFH with aPTT prolongation, there was poor concordance between aPTT and anti-factor Xa. This suggests that aPTT prolongation may not be solely driven by heparin activity and further evaluation of mechanistic drivers for coagulopathy in this population is necessary.
引用
收藏
页码:221 / 227
页数:7
相关论文
共 50 条
  • [1] Concordance between Anti-Factor Xa and Activated Partial Thromboplastin Time Measurements in Syncardia Total Artificial Heart Recipients Receiving Postoperative Anticoagulation with Unfractionated Heparin
    Vela, M. Monteagudo
    Bowles, C.
    Raj, B.
    Simon, A.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (04): : S447 - S447
  • [2] ANTI-FACTOR XA VERSUS ACTIVATED PARTIAL THROMBOPLASTIN TIME FOR HEPARIN INFUSION MONITORING
    Jung, Sul
    Choi, Austin
    Lepore, Mark
    CRITICAL CARE MEDICINE, 2020, 48
  • [3] SAFETY OF MONITORING UNFRACTIONATED HEPARIN INFUSIONS IN CRITICALLY ILL PATIENTS: ANTI-FACTOR XA VERSUS ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT)
    Burka, Abigail
    Cunningham, Michael
    Ernst, Neil
    Droege, Chris
    Hillebrand, Kristen
    Clark, Lindsey
    Tsuei, Betty
    Mueller, Eric
    CRITICAL CARE MEDICINE, 2012, 40 (12) : U279 - U279
  • [4] Anti-factor Xa activity, prothrombin time, and activated partial thromboplastin time in patients treated with factor Xa inhibitors
    Ono, Ryohei
    Nishimura, Kazutaka
    Takahashi, Hidehisa
    Hori, Yasuhiko
    Fukushima, Kenichi
    Kobayashi, Yoshio
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2023, 396 (02) : 323 - 336
  • [5] Comparison Between Activated Partial Thromboplastin Time and Anti-Xa Heparin Assays on Patients on Unfractionated Heparin Therapy
    Pearlman, Eugene
    Bibars, Wafi
    Willard, Jennifer
    Moore, Darlene
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2015, 144 : A127 - A127
  • [6] Anti-factor Xa activity, prothrombin time, and activated partial thromboplastin time in patients treated with factor Xa inhibitors
    Ryohei Ono
    Kazutaka Nishimura
    Hidehisa Takahashi
    Yasuhiko Hori
    Kenichi Fukushima
    Yoshio Kobayashi
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, 396 : 323 - 336
  • [7] Anti-Factor Xa and Activated Partial Thromboplastin Time Measurements for Heparin Monitoring in Mechanical Circulatory Support
    Adatya, Sirtaz
    Uriel, Nir
    Yarmohammadi, Hirad
    Holley, Christopher T.
    Feng, Amy
    Roy, Samit S.
    Reding, Mark T.
    John, Ranjit
    Eckman, Peter
    Zantek, Nicole D.
    JACC-HEART FAILURE, 2015, 3 (04) : 314 - 322
  • [8] Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin
    Ratano, Damian
    Alberio, Lorenzo
    Delodder, Frederik
    Faouzi, Mohamed
    Berger, Mette M.
    THROMBOSIS RESEARCH, 2019, 175 : 53 - 58
  • [9] Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy
    Lawlor, Matthew
    Gupta, Aakriti
    Ranard, Lauren S.
    Madhavan, Mahesh V.
    Li, Jianhua
    Eisenberger, Andrew
    Parikh, Sahil A.
    Sethi, Sanjum S.
    Masoumi, Amirali
    THROMBOSIS RESEARCH, 2021, 198 : 79 - 82
  • [10] Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin
    Wahking, Rebekah A.
    Hargreaves, Rachel H.
    Lockwood, Sean M.
    Haskell, Sabrina K.
    Davis, Kelly W.
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (08) : 801 - 805